|
1
|
Li J, Kang LN and Qiao YL: Review of the
cervical cancerdisease burden in mainland China. Asian Pac J Cancer
Prev. 12:1149–11453. 2011.PubMed/NCBI
|
|
2
|
Tanimoto H, Yan Y, Clarke J, Korourian S,
Shigemasa K, Parmley TH, Parham GP and O'Brien TJ: Hepsin, a cell
surface serine protease identified in hepatoma cells, is
overexpressed in ovarian cancer. Cancer Res. 57:2884–2887.
1997.PubMed/NCBI
|
|
3
|
Ulloa L and Messmer D: High-mobility group
box 1 (HMGB1)protein: friend and foe. Cytokine Growth Factor Rev.
17:189–201. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kong TW, Piao X, Chang SJ, Paek J, Lee Y,
Lee EJ and Ryu HS: A predictive model for parametrial invasion in
patients with FIGO Stage IB cervical cancer: individualized
approach for primary treatment. Int J Gynecol Cancer. 26:184–191.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ohmori H, Luo Y and Kuniyasu H:
Non-histone nuclear factor HMGB1 as a therapeutic target in
colorectal cancer. Expert Opin Ther Targets. 15:183–193. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chung HW, Lee SG, Kim H, Hong DJ, Chung
JB, Stroncek D and Lim JB: Serum high mobility group box-1 (HMGB1)
is closely associated with the clinical and pathologic features of
gastric cancer. J Transl Med. 7:382009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moriwaka Y, Luo Y, Ohmori H, Fujii K,
Tatsumoto N, Sasahira T and Kuniyasu H: HMGB1 attenuates
anti-metastatic defense of the lymph nodes in colorectal cancer.
Pathobiology. 77:17–23. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cebrián MJ, Bauden M, Andersson R,
Holdenrieder S and Ansari D: Paradoxical role of HMGB1 in
pancreatic cancer: tumor suppressor or tumor promoter? Anticancer
Res. 36:4381–4389. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Liu Z, Du R, Long J, Guo K, Ge C, Bi S and
Xu Y: microRNA-218 promotes gemcitabine sensitivity in human
pancreatic cancer cells by regulating HMGB1 expression. Chin J
Cancer Res. 27:267–278. 2015.PubMed/NCBI
|
|
10
|
Bandiera A, Bonifacio D, Manfioletti G,
Mantovani F, Rustighi A, Zanconati F, Fusco A, Di Bonito L and
Giancotti V: Expression of HMGI(Y) proteins in squamous
intraepithelial and invasive lesions of the uterine cervix. Cancer
Res. 58:426–431. 1998.PubMed/NCBI
|
|
11
|
Fu X, Du XQ and Hao H: Study on the
expression and clinical significance of high mobility group protein
HMGB1 in cervical squamous cell carcinoma. Chinese Journal of
Cancer Control. 15:357–359. 2008.
|
|
12
|
Sheng X, Du X, Zhang X, Li D, Lu C, Li Q,
Ma Z, Song Q and Wang C: Clinical value of serum HMGB1 levels in
early detection of recurrent squamous cell carcinoma of uterine
cervix: comparison with serum SCCA CYFRA21-1, and CEA levels. Croat
Med J. 50:455–464. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mitola S, Belleri M, Urbinati C, Coltrini
D, Sparatore B, Pedrazzi M, Melloni E and Presta M: Cutting edge:
extracellular high mobility group box-1 protein is a proangiogenic
cytokine. J Immunol. 176:12–15. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Weng H, Deng Y, Xie Y, Liu H and Gong F:
Expression and significance of HMGB1, TLR4 and NF-κB p65 in human
epidermal tumors. BMC Cancer. 13:3112013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang JL, Wu DW, Cheng ZZ, Han WZ, Xu SW
and Sun NN: Expression of high mobility group box-B1 (HMGB-1) and
matrix metalloproteinase-9 (MMP-9) in non-small cell lung cancer
(NSCLC). Asian Pac J Cancer Prev. 15:4865–4869. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yin M, Xu Y, Lou G, Hou Y, Meng F, Zhang
H, Li C and Zhou R: LAPTM4B overexpression is a novel predictor of
epithelial ovarian carcinoma metastasis. Int J Cancer. 129:629–635.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lipari MT, Li W, Moran P, Kong-Beltran M,
Sai T, Lai J, Lin SJ, Kolumam G, Zavala-Solorio J, Izrael-Tomasevic
A, et al: Furin-cleaved proprotein convertase subtilisin/kexin type
9 (PCSK9) is active and modulates low density lipoprotein receptor
and serum cholesterol levels. J Biol Chem. 287:43482–43491. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Goulet B, Chan G, Chambers AF and Lewis
JD: An emerging role for the nuclear localization of maspin in the
suppression of tumor progression and metastasis. Biochem Cell Biol.
90:22–38. 2012.PubMed/NCBI
|
|
19
|
Secord A Alvarez, Darcy KM, Hutson A,
Huang Z, Lee PS, Jewell EL, Havrilesky LJ, Markman M, Muggia F and
Murphy SK: The regulation of MASPIN expression in epithelial
ovarian cancer: association with p53 status, and MASPIN promoter
methylation: a gynecologic oncology group study. Gynecol Oncol.
123:314–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zhang C, Zhang M, Wu Q, Peng J, Ruan Y and
Gu J: Hepsin inhibits CDK11p58 IRES activity by suppressing unr
expression and eIF-2α phosphorylation in prostate cancer. Cell
Signal. 27:789–797. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang M, Zhao J, Tang W, Wang Y, Peng P,
Li L, Song S, Wu H, Li C, Yang C, et al: High Hepsin expression
predicts poor prognosis in gastric cancer. Sci Rep. 6:369022016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pelkonen M, Luostari K, Tengström M,
Ahonen H, Berdel B, Kataja V, Soini Y, Kosma VM and Mannermaa A:
Low expression levels of hepsin and TMPRSS3 are associated with
poor breast cancer survival. BMC Cancer. 15:4312015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Stephan C, Yousef GM, Scorilas A, Jung K,
Jung M, Kristiansen G, Hauptmann S, Kishi T, Nakamura T, Loening
SA, et al: Hepsin is highly overexpressed in and a new candidate
for a prognostic indicator in prostate cancer. J Urol. 171:187–191.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Matsuo T, Nakamura K, Takamoto N, Kodama
J, Hongo A, Abrzua F, Nasu Y, Kumon H and Hiramatsu Y: Expression
of the serine protease hepsin and clinical outcome of human
endometrial cancer. Anticancer Res. 28(1A): 159–164.
2008.PubMed/NCBI
|
|
25
|
Lucas JM, True L, Hawley S, Matsumura M,
Morrissey C, Vessella R and Nelson PS: The androgen-regulated type
II serine protease TMPRSS2 is differentially expressed and
mislocalized in prostate adenocarcinoma. J Pathol. 215:118–125.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wilson S, Greer B, Hooper J, Zijlstra A,
Walker B, Quigley J and Hawthorne S: The membrane-anchored serine
protease, TMPRSS2, activates PAR-2 in prostate cancer cells.
Biochem J. 388:967–972. 2005. View Article : Google Scholar : PubMed/NCBI
|
